Movatterモバイル変換


[0]ホーム

URL:


CA1070612A - Solid phase immunofluorescent assay method - Google Patents

Solid phase immunofluorescent assay method

Info

Publication number
CA1070612A
CA1070612ACA255,623ACA255623ACA1070612ACA 1070612 ACA1070612 ACA 1070612ACA 255623 ACA255623 ACA 255623ACA 1070612 ACA1070612 ACA 1070612A
Authority
CA
Canada
Prior art keywords
unknown
particles
antigen
antibody
immune reactant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA255,623A
Other languages
French (fr)
Inventor
Robert V. Dahlstrom
Michael W. Burgett
James F. Monthony
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bio Rad Laboratories Inc
Original Assignee
Bio Rad Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Rad Laboratories IncfiledCriticalBio Rad Laboratories Inc
Application grantedgrantedCritical
Publication of CA1070612ApublicationCriticalpatent/CA1070612A/en
Expiredlegal-statusCriticalCurrent

Links

Classifications

Landscapes

Abstract

SOLID PHASE IMMUNOFLUORESCENT ASSAY METHOD
Abstract of the Disclosure An assay method suitable for antigens (or haptens) including proteins and polypeptides utilizing antibodies for the unknown protein or polypeptide in which the anti-bodies are covalently bound to water insoluble hydro-phylic polymeric particles. Appropriate fluorescently labeled immune reactants are introduced during the method and together with the unknown antigen are immunologically bound, directly or indirectly, to the particles for separa-tion from the reaction liquid. The particles have a size of about .1-10 microns and can be resuspended for direct measurement of the fluorescent labels in a fluorometer from which the unknown can be determined.

Description

This invention relates to a method for the immunofluorescent assay of antigens (or haptens) and their antibodies. More particularly, it relates to the use of an immune reactant related to the antibody or antigen 5 (or hapten) to be determined which is covalently bonded -~
or coupled to polymeric particles whose size permit direct measurement of a labeled immunological reagent's fluorescence in an aqueous suspension thereof.
The covalent coupling of antigens (or haptens) and antibodies to water insoluble polymers is well documented.
Typical reports on this topic are:
Campbell, D.H., Leusher, E., and Lerman, L.S.
Proc. Nat. Acad. U.S. 37, 575 (1951) Weliky, N. and Weetall, H.H., Immunochemistry
2, 293 (1965) Campbell, D.H., and Weliky, N., Methods in Immunology and Immunochemistry, Editors:
Williams C.A. and Chase, M.W. Vol. 1, Academic Press, N.Y. (1967~

' .; ~

. - ~

~-~ 1070612 The technique has been used to detect various con-stituents and is the subject of several patents. In U.S.
Patent No. 3,555,143 issued January 12, 1971 to R.E.A.V.
Axen, et al., the patentees covalently bound antibodies S to water insoluble polymers, mixed them with radioactive protein and unlabeled protein in a competitive binding technique.
In U.S. Patent No. 3,867,517 issued February 18, 1975 the patentee Chung-Mei Ling coated a test apparatus with hepatitis associated antibody or antigen, then con-tacted the apparatus with a solution containing the antigen or antibody. Thereafter this was exposed to hepatitis antigen or antibody labeled with radioactive isotope I125 to give a sandwich. After washing, the amount of isotope lS attached could be quantitated.

~07061Z
1 Molday, et al (Molday, R.S., Dreyer, W.J., Rembaum, A.
2 and Yen, S.P.S., Nature 249, May 3, 1974) and (The Journal
3 of Cell Biology, Vol. 64, 75-88, 1975) report on the
4 synthesis of latex spheres equal to or less than 1300 A in diameter, the fluorescent or radioactive ta~ging of the 6 spheres, and the covalent bonding of antibodies to the 7 spheres. These were subsequently used to locate antigens on 8 cell surfaces.
9 In~an & Dintzis (Inman, J.K. and Dintzis, H.~., Biochemistr~ 8 (10~ 4074-4082, 1969) described the chemical 11 modification of polyacrylamide beads to introduce a wide 12 variety of functional groups. The chemically reactive bead 13 derivatives were used to covaIently link antibodies or 14 enzymes.
Ohno and Stahmann (Ohno, Y. and Stahmann, M.A., 16 Immunochemistry 9, 1087-1093, 1972) subsequently determined 17 that beads of about 10 microns in size, to which penicillin 18 had been attached, gave better agglutination reactions than 19 red blood cells when used in detecting antibodies to penicillin.
21 Immunochemical labeling techniques have been reviewed 22 in Methods in Immunology and Immunochemistry, Editors:
23 Williams, C.A. and Chase, M.W., Vol. 1, Acad. Press, N.Y.
24 (1967) and Vol. III (1971).
The use of fluorescently Iabeled antibodies has been 26 reviewed by Coons (Coons, A.H., Fluorescent Antibody Methods, J.F. Danielli (Editors) General Cytochemical 28 Methods, Vol. 1, Academic Press, N.Y. 195~) and has found 29 widespread use in the detection of microbial and tissue 30 antigens by fluorescent microscopy.

':~

Coons, et al (Weller, T.H. and Coons, A.H.) Proc. Soc.
Exptl. Biol. Med. 86, 789 (1954) also described a method of determining cell bound antigen using a specific antibody plus a fluorescent anti-gamma globulin antibody.
The same authors (Coons, A.H., Leduc, E.H. and Connolly, J.M., J. Exptl. Med. 102, 49, 1955) described a technique for determining cell bound antibody by using specific antigen plus specific fluorescent antibody.
Capel (Capel, P.J.A., J. of Immunological Methods 5, 165-178, 1974) coupled antibodies or antigens to the surface of agarose beads of a size ranging from 40-190 u. In this work he had to adjust conditions to prevent the antigen from penetrating the pores of the bead or the ensuing anti-gen-antibody reaction would be hindered. In his work he attached human IgG to agarose beads, reacted them with rabbit anti-human IgG antibody and then fluorescein iso-thiocyanate (FITC) labeled horse anti-rabbit Ig serum.
He measured the amount of fluorescence attached by visualiza-tion with fluorescent microscopy. If antigen was to be measured, the anti-human IgG antibody was attached to the agarose beads, reacted with human IgG and FITC labeled horse anti-human Ig serum added and the fluorescence deter-mined by fluorescent microscopy.
By way of summary, in the application of covalently coupled immune reactants with insoluble polymers to assays, immune reactants labeled with either radioactive tracers or fluorescent compounds have been employed. Radioactive tracers have the disadvantages of limited life and special handling requirements, as well as requiring ~"`' ` 107061Z
1 expensive detection instrumentation. With respect to the 2 prior use of fluorescent tracers, applications that might be 3 considered an assay have been limited to indirect or 4 relatively tedious and time consuming procedures such as measuring fluorescence of individual particles by 6 visualization with fluocescent microscopy.
7 The method of the present invention permits measurement 8 of fluorescently labeled part1cles by direct optical 9 spectroscopy. The key to the method is in the selection of polymeric particle sizes which provide a substantially 11 homogeneous suspension during execution of the assay. It 12 has been discovered that such a condition exists upon which 13 direct fluorometric measurements can be made where the .
14 polymeric particles have a size of about .l-lO microns and preferably where the particles have a size distribution 16 within this range centered about 5 microns.
17 Utilizing such particles, an appropriate immune 18 reactant immunologically related to unknown antigen (or hapten) or antibody to be determined is covalently bonded thereto. The particles, unknown immune reactant, and 21 appropriate fluorescently labelled immune reactant are mixed 22 under conditions so that a quantity of the labelled immune 23 reactant proportional to the concentration of the unknown 24 immune reactant is immunologically bound, directly or indirectly, to the particles. The particles can then be 26 readily physically separated and their fluorescence directly 27 r,leasured by fluorometry.

~ 301
-5-.. ~
' As used herein, "immunologically related" means that , .
the immune reactant is either the same as the immune reac-tant being referred to or its homolog. An antibody is the "immunological homolog" of an antigen which produced it and vice versa. In the methods of this invention antigens and haptens perform entirely analogous functions. This will be indicated by referring to them as alternatives throughout.
More particularly, the present invention provides an improved immunofluorencence assay comprising providing a plurality of water insoluble hydrophilic polymeric particles of about .l-10 microns in size and having covalently bonded thereto an immune reactant immunologically related to an unknown immune reactant to be determined, providing an appropriate amount of fluorescently labeled immune reactant immunologically related to said unkno-~n, immunologically binding said particles in aqueous solution with a quantity of said labeled immune reactant proportional to the concentration of saidunknown, separating said particles from said aqueous solution, and measuring the fluorescence of an aqueous suspension of said aqueous particles by fluorometry to obtain information from which the concen-tration of said unknown immune reactant can be determined.
The immune reactant is preferably an immunological homolog for the antigen (or hapten) or antibody to be determined.

107061~ ~

1 The method is especially suited ~or deter~lning 2 antigens (or haptens) selected from protein~i and 3 polypeptides utilizing antibodies a~ainst the pLo~ein or 4 polypeptide. These antibodies are covalent1y bound to suitable water insoluble polymeric particles. Thus, in a
6 preferred embodiment the improved assay comprises providing
7 a plurality of water insoluble hydrophylic polymeric
8 particles of about .l-lO microns in size and having
9 covalently bonded thereto-antibody for unknown antigen (or hapten) to be determined. Unknown antigen (or hapten) is 11 immunologically bound to said particles in aqueous solution.
12 In addition, fluorescently labeled immune reactant 13 is combined to immunologically bind a portion thereof either 14 directly or indirectly (through bound antigen or hapten) to said particles so that the bound labels are separable with 16 said particles. The particles are separated from unbound 17 immune reactant and the fluorescence of a fluid suspension 18 is measured in a fluorometer to obtain information for the 19 assay of unknown antigen (or hapten).
Any suitable water insoluble polymeric particle may be 21 utilized. Generally the particle will be in spherical or 22 bead form and will be selected from polymers which can be 23 derivatized to give a terminal primary amine, terminal 24 carboxyl, or hydrazide group. The antibody or antigen (or hapten) is then immobilized on the~particle under 26 conventional reaction conditions to produce a covalent ~7-l, ~ ' ' bond therebetween. PreEerred polymeric particles are formed 21 from cross-linked polyacrylami~es. Immobilization of immune 31 reactants on such preferred substrates are reported by Inman I ~ Dintzis as cited above. Other suitable polymeric 51 particles include those reported in u.s. Patent No.
61 3,555,143 in particular, as-well as the other references 7 ¦ above cited.
8 ¦ In carrying out the present assay method, a number 9 ¦ of alternative techniques are available. The choice will
10 ¦ usually be made depending upon the nature of the particular
11 ¦ antigen (or hapten) or antibody to be determined and their
12 ¦ availability. In general one of the following sequences
13 ¦ will provide the most satisfactory option:
14 ¦ Sandwich Technique
15 j The immobilized antibody (covalently attached to the
16 ¦ polymeric particle, preferably in spherical or bead form) is
17 ¦ reacted in an appropriate solution with specific bivalent or
18 ¦ multivalent antigen (or hapten) in such concentrations that
19 I there is always an excess of antibody. After the reaction has gone to completion, fluorescently labeled antibody 21 specific to the antigen (or hapten) is added in slight 22 excess. Since the antigen (or hapten) has two or more sites 23 for reaction and only one is occupied, the second labeled 24 antibody will react with the unoccupied antigen (or hapten) site(s). The antibody beads, combined with the antigen (or 26 hapten) and labeled antibody, are separated and measured in 27 a fluorometer. The concentration of the antigen (or hapten) 28 is directly related to the amount of fluorescence attached to the beads.

-"` 107061Z
~, Sequential Saturation Another approach is to react an excess of the immob-ilized antibody with the antigen (or hapten) in question.
After the reaction has occurred, labeled antigen (or hapten) can be added which will occupy the available sites remaining on the antibody. The immobilized antibody-antigen (or hapten) complex can be separated and the label measured.
The amount of labeled antigen (or hapten) immobilized will be inversely related to the amount of antigen (or hapten) in the sample. This approach may be necessary in the case of monovalent antigens (or haptens). ~ -Antigen Excess When antigen (or hapten) is in excess a competitive binding technique may be employed. Antibody specific for an antigen (or hapten) is attached to the particles. The amount of bound or solid phase antibody added to the system is sufficient to bind a limited amount of antigen (or hap-ten). The specific antigen (or hapten) in question and homologous labeled antigen (or hapten) are added to the antibody. Since the number of binding sites on the immob-" ilized antibody is limited, the labeled and unlabeled anti-gens (or haptens) will compete for the sites. The amount of labeled antigen (or hapten) bound will be inversely related to the concentration of unlabeled antigen (or hapten) in the system and can be used as a means of quanti-tation of the unlabeled antigen (or hapten) in the system.
This technique can be combined with a second antibody technique. By the correct selection of an antibody fraction, the solid phase antibody can be used as a second antibody in the analyses, for example, of haptens that have only one combining site with antibodies. In this procedure, 1¦ antibodies to a hapten, such as thyroxine, dinitroE)henol or 21 a steroid are prepared by well known procedures. The hapten 31 is conjugated with the protein of one species and injected 4¦ into a noncompatible species. That is, the hapt~n can be 51 conjugated to human serum albumin and injected into rabbits.
6 ¦ The rabbit will produce antibodies against the protein-7 ¦ hapten conjugate.
8 ¦ In this procedure, a second antibody is required 9 1 and second antibodies are produced against, for example, a 10¦ fracti-on of rabbit globulins by injecting them into a goat.
11 ¦ This produces goat anti-rabbit antibodies. These can be 12 ¦ conjugated to small polyacrylamide beads, for example, and 13 ¦ used as a second antibody for any system in which the first 14 ¦ antibody was produced in rabbits. ~ny series of animals may 15 1 be used as long as antibodies against the first species are 16 ¦ produced in a noncompatible second species.
17 ¦ In this procedure, the antibody-hapten or antigen 18 ¦ combination does not differ significantly from unreacted 19 ¦ antibody to allow convenient separation or precipitation. A
20 ¦ second particle bound antibody, to the globulin fraction of
21 ¦ the animal used to produce the first antibody, is utilized
22 ¦ to cause precipitation to occur. In this case, the ¦ initially competitively bound antigen-first antibody 24 ¦ combination~may be considered the immunological homolog of the particle bound second antibody.

32 -lO-:

~1070612 In another technique, hapten protein conjugates are used in a manner analogous to that described above for preparing antibodies to haptens. The antibodies to the hapten are covalently linked to the polyacrylamide beads to be used as a reagent for the determination of a hapten. Then the same hapten protein conjugate is prepared ~ -and the protein fluorescently labelled. This is used in a competitive binding assay or sequential saturation assay with the native hapten to be assayed. The technique provides an amplified molar fluorescent response.
Another variation of the technique is to covalently bind the antigen to the bead. The antigen bound to the bead is placed in competition with native antigen for limited amount of homologous antibody. The beads are separated and reacted with an excess of a fluorescently labelled second antibody directed against the antigen-antibody complex. The beads can be separated and the fluorescence measured. The amount of fluorescence is inversely related to the serum concentration of antigen to be measured.

, .

'`-` 107061Z

The present invention contemplates the use of any suitable fluorescent compound in combination with antigens (or haptens) or antibodies as a label. The following are typical examples of suitable compounds, together with references pertaining to their use as labels.
1. Fluorescein-isothiocyanate The, ~. H. and Feltkamp, T.E.W., Immunology, 18,865 (1970) 2. Rhodamine B isothiocyanate Chen, R.F. Arch. Biochem. Biophys. 133, 263 (1969) 3. DNS chloride (5-dimethylamino-1-naphthalene sulfonylchloride) Weber, G., Biochem J., 51,155 (1952) 4. NBD chloride (7-chloro-4-nitro-benzo-2-oxa-1, 3,-diazole) Ghosh, P.B. and Whitehouse, M.W., Biochem. J., 108, 155 (1968) 5. MDPF (2-methoxy-2,4-diphenyl-3(2H)-furanone) Weigele, M., DeBernardo, S., Leimgruber, W., Cleeland, R. and Grunberg, E., Biochem. Biophys.
Res. Comm. 54,899 (1973) 6. Fluorescamine (Flu~am -Roche Diagnostics) Bohlen, P., Stein, S., Dairman, W. and Udenfriend, S., Arch. Biochem. Biophys. 155, 213 (1973) 7. O-Phthalaldehyde Benson, J.R. and Hare, P.E., Proc. Nat. Acad.
; Sci. (USA) 72, 619 (1975) 8. ANS (9-anilinonaphthalene-1-sulfonate) Hartman, B.K. and Udenfriend, S., Anal. Biochem.
30, 391 (1969).

: 10~061Z

1 TYPICAL GENERAL PROCE:D~RES
2 I. P~PA~TION OF ANTIBODY L3E~I)S
3 A. ~erivatized polyacrylamide beads, havin(3 a 4 functional capacity of 0.25 meq/g to 6 meq/g, are used for antibody attachment. (These may be 6 obtained from Bio-Rad Laboratories of Richmond, 7 California, as Affi-Gel 701" 702, 703 or 8 derivative thereof.) 9 In addition, polyacrylamide beads, with an exclusion limit of 6-7,000 daltons, may be 11 hydrolyzed by treatment with 2 M NaOH for 18 hours 12 at 40C. The beads are neutralized with I~Cl and 13 washed with deionized water. The carboxyl 14 capacity of the beads is measured by direct titration and preferably should be about 6 meq/g 16 dry weight.
17 B. Carboxylate beads are suspended in 0. 003 M
18 phosphate buffer, pH 6.3, to a final concentration 19 of 10 mg beads/ml.
C. A globulin fraction of an antiserum, specific 21 for the antigen under test, is added to the beads 22 at a concentration of 12 ug antibody/mg of beads.
23 The reaction mixture is adjusted to p~ 6. 3.
24 D. A water soluble carbodiimide such as l-ethyl-3(3-dimethylaminopropyl) carbodiimide (EDAC) is added 26 at a concentration of 0.25 meq EDAC/meq of 27 functional capacity of the bead. The reaction is 28 maintained at pH 6. 3 for one hour by the addition 29 of dilute acid and/or base. After the first hour, the pH usually remains constant and the reaction 31 is allowed to proceed over night at 4C.

' , .

~ 107061Z

1¦ ~. The coupled beads are washed twice ~ith PBS
2 ¦ (physiologically bufEered saline, 0.15 M NaCl -31 0.01 M phosphate bufEer, pH 7.2), three times with 4 ¦ 5M guanidine HCl in 0.05 ~I phosphate buffer, pH
¦ 7.5, two more times with PBS and finally twice 6 ¦ with 0.005 M phosp'nate buffer, pH 7.5. The volume 7 ¦ of the washes was about 50 mljlOO mg beads. The 8 I washes are carried out at 4C for maximal antibody 9 ¦ activity.
10 ¦ F. The beads may be stored in 0.005 M phosphate 11 ¦ buffer containing 0.01~ sodium azide at 4C.
12 ¦ II. ANTIGEN EXCESS ASSAY (Competitive Binding Assay) 13 ¦ A. Aliquots of 200 ul of a 10 mg/ml antibody bead 14 ¦ suspension (~2 mg antibody beads) are added to a 15 ¦ 13 x 100 mm borosilicate test tube containing 1.1 16 I ml of PBS. The beads are pelleted by 17 ¦ centrifugation ~V8,000g for~vl min.) 18 ¦ B. The reaction is started by the addition of 10 ul 19 ¦ labeled antigen (containing 10 mg antigen/ml), a 20 ¦ sample of serum (10 ul of whole serum should fall 21 ¦ in the range of the assay for lgG) and enough PBS
22 ¦ to bring the assay mix to 1.5 ml. The mixture is 23 ¦ shaken with a vortex mixer and incubated for 30 24 ~ minutes at room temperature.

310 ~

, I

~ `` 107061Z
C. At 30 minutes, 4 ml of PBS is added to the -~ assay mix. The sample is mixed and then centri-fuged as above. The supernatant fluid is carèfully discarded and the pellet is resus-pended in 5 ml PBS. After about 10 minutes the suspension is recentrifuged and the supernatant fluid is again discarded.
D. The amount of labeled antigen on the beads is directly determined in a fluorometer. The quantity of labeled antigen picked up by the test sample is divided by the quantity pic~ed , up by a control sample tantibody beads plus labeled antigen with no serum) and plotted as a~function of the concentration of antigen in mg/ml on log logit paper.
III. SANDWICH ASSAY
A. Aliquotes of 200 ul of a 10 mg/ml antibody bead suspension (~2 mg antibody beads) are added to a 13 X 100 mm borosilicate test tube containing 1.2 ml of PBS. The beads are pelleted by , centrifugation (~8,000 g for~ 1 min.) B. A dilution of the serum is made (~1:1000 for IgG, 100 for IgM and IgA). A 100 ul aliquot of the dilution is added to the tube from (A).
The sample is mixed with a vortex mixer and allowed to incubate at room temperature for 3 hours.

.
, .
'~

,~ .

.

C. A lO0 ul aliquot of labeled antibody which should contain 20-50 ug antibody is added to the tube from (B) and the mixture is incubated an additional 30 minutes.
D. At 30 minutes, 4 ml of PBS is added to the assay mix. The sample is mixed and then centri-fuged as above. The supernatant fluid is care-fully discarded and the pellet is resuspended in 5 ml PBS. After about 10 min. the suspension is recentrifuged and the supernatant fluid is again discarded.
E. The relative fluorescence of labeled antibody on the bead is determined and this valve is plotted versus the concentration of antigen in ug on log-log paper.
The following examples of specific embodiments will illustrate the invention in connection with rabbit anti-human IgG (Ro~HIgG) coupled to cross-linked polyacrylamide beads. In the drawings referred to in the Examples:
Figures l and 2 both relate relative fluorescence to antigen concentration.

~ . :

1 l EXAMPLE 1 21 A gram sample of terpolymer microbeads (less than 10 3 microns in diameter) was hydrolyzed by treatment with 2M
41 NaOH for 18 hours at 40C. The beads were neutralized with I HCl and washed six times with DI (de-ionized) H2O.
61 A 500 mg sample of the above hydrolyzed beads was 71 suspended in 100 ml 0.003 M phosphate buffer, pH 6.3. A 2 8 ¦ ml aliquot of an IgG fraction of rabbit anti-human IgG serum 9¦ (Miles, Lot 14, Code 64-155) contained 2.9 mg/ml antibody in 10¦ a 1% protein solution. The pH of the reaction mixture was 11¦ adjusted to 6.3. An aliquot of 130 mg of EDAC (Bio-Rad) was 12¦ added and the pH of the mixture was maintained at 6.3 with ~3¦ the addition of dilute acid and base for one hour. The 14¦ reaction was allowed to proceed overnight with stirring at ~5¦ 4C. The beads were washed twice with ~100 ml PBS, three 16¦ times with 100 ml of 5 M guanidine HCl containing 0.01 M
'71 phosphate buffer, pH 7.5, and twice more with 100 ml PBS.
18¦ After three hours at 4C the beads were washed twice with 19¦ 100 ml of 0.005 M phosphate buffer, pH 7.5, and then 20¦ suspended and stored in 50 ml of the last buffer containing 22 0.01% sodium azide (final concentration, 10 mg beads/ml).
I, 231 .

24 ~
251 ., 33l 1 1 EX~MPLE 2 2 ¦ Antigen ~xcess Assay 3 ¦ A 200 ul (2 mg) aliquot of R~ HIgG beads from ~xample l 4 ¦ was added to 1200 ul of PBS in a series of l.5 ml Eppendorf 5 ¦ centrifuge tubes. The beads were pelleted in an Eppendorf ¦ centrifuge ;~odel 3200/30 by centrifugation at maximum speed 7 ¦ for l minute (~12,000 g). A lO ul aliquot of FITC labeled 8 ¦ Human IgG (Cappel), various dilutions of ~1ormal Human serum 9 ¦ and enough PBS to bring the assay mix to l.5 ml was added to 10 ¦ each sample. The reaction was initiated by resuspending the 11 ¦ beads with a vortex mixer. After 30 minutes the beads were 12 ¦ centrifuged as above and the supernatant fluid was decanted.
13 ¦ The beads were washed by resuspension in 1.5 ml PBS followed 14 ¦ by centrifugation as above. The supernatant fluid was again 15 ¦ poured off. This process was repeated once and the beads 16 ¦ were resuspended in 5 ml 0.005 M Tris HCl, p~ 8.5. The 17 ¦ fluorescence of the beads was determined using a Turner 18 ¦ Filter Fluorometer with filter 47B for the excitation light 19 ¦ and filter 2Al2 for the emission light.
20 1 The fluorescence of a tube containing a ~2 mg 21 ¦ suspension of untreated beads is subtracted from the 22 ¦ fluorescence of each test sample. The fluorescence of the 23 ¦ test sample is then divided by the fluorescence of the 24 ¦ control beads (Ab beads + fluorescent antigen with no serum
25 ¦ added) and plotted versus concentration of antigen in mg on 27 log-logit paper as shown in Figure l.

~ -18-, . ~ ' , .

` 1070612 2 Sandwich Assay 3 The following components were mixed in a ~ppendorf 4 centrifuge tube and incubated ~or 18 hours at room temperature. 200 ul of R~ HIgG beads from Example 1, 1,200 ul of PBS containing 1~ BSA and 100 ul of a normal human 7 serum dilution. At 18 hours the beads were centrifuged down 8 in an Eppendorf Model 3200/30 at maximu~ speed for one 9 minute (~12,000 g) and the supernatant fluid was decanted off. The beads were washed by resuspension in 1.5 ml PBS
11 and centrifuged as above. The supernatant fluid was 12 decanted off and the beads were resuspended in 1 ml of PBS
13 containing 1~ BSA. A 10 ul aliquot of FITC conjugated R~
14 HIgG (Miles Lot 19, Code 64-169) was added to the beads and they were allowed to react at room temperature. After 30 16 minutes the beads were centrifuged and washed twice with P8S
17 as above. The beads were resuspended in 5 ml 0.005 M Tris 18 HCl, pH 8.5. The Eluorescence of the beads was determined 19 with a Turner filter fluorometer using a ~7B filter for the excitation light and a 2A12 filter for the emission light.
21 The fluorescence of the test sample less the fluorescence of 22 a blank sample (a sample containing bead which had not been 23 exposed to serum but was reacted with fluorescent antibody) 24 was plotted versus IgG concentration in ug on log-log paper as shown in Flgure 2.

3l~ i 32 ` -19-' . , .

Claims (25)

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:-
1. An immunofluorescent assay comprising:
providing a plurality of water insoluble hydrophi-lic polymeric particles of about .1-10 microns in size which form a substantially homogeneous stable aqueous suspension and having covalently bonded thereto an immune reactant immunologically related to an unknown reactant to be deter-mined, providing a sample of unknown immune reactant to be determined, providing an appropriate amount of fluorescently labeled immune reactant immunologically related to said unknown, reacting said particles, sample, and labeled immune reactant to immunologically bind said particles in aqueous solution with a quantity of said labeled immune reactant proportional to the concentration of said unknown, physically separating all of said particles from said aqueous solution thereby separating the particles from unbound labeled immune reactant remaining in the aqueous solution, and measuring the fluorescence of an aqueous suspension of said separated particles by direct fluorometric measurement, the fluore-scence of labeled immune reactant bound to said particles being quantitatively related to the concentration of said unknown immune reactant.
2. An assay according to claim 1 wherein said fluorescently labeled immune reactant is the immunological homolog of said unknown immune reactant.
3. An assay according to claim 1 wherein said fluorescently labeled immune reactant is the same as said unknown immune reactant.
4. An assay according to claim 2 wherein the particle bound immune reactant is the immunological homolog of said unknown.
5. An assay according to claim 3 wherein the particle bound immune reactant is the immunological homolog of said unknown.
6. An assay according to claim 4 wherein the particle bound immune reactant is antibody for said unknown, and said reacting further comprises immunologically binding said particles with said unknown and combining said fluore-scently labeled immune reactant with said particles to immunologically bind a portion thereof.
7. An assay according to claim 5 wherein the particle bound immune reactant is antibody for said unknown, and said reacting further comprises immunologically binding said particles with said unknown and combining fluorescently labeled immune reactant with said particles to immunolo-gically bind a portion thereof.
8. An assay according to claim 6 wherein said unknown is a hapten or antigen which is bivalent or multi-valent, said particles have covalently bonded thereto antibody for said unknown, are present in excess relative to said unknown, and are first reacted with said unknown, said labeled immune reactant is antibody for said unknown and is reacted therewith subsequent to said particle bound anti-body whereby said unknown is immunologically bound both by said particles and said fluorescently labeled antibody for separation with said particles.
9. An assay according to claim 7 wherein said unknown is hapten or antigen, said particles have covalently bonded thereto antibody for said unknown, are present in excess of said unknown, are first immunologically bound to said unknown preceding combination with fluorescently labeled immune reactant and thereafter said fluorescently labeled immune reactant is immunologically bound to the excess-antibody of said particles.
10. An assay according to claim 2 wherein the particle bound immune reactant is the same as said unknown immune reactant.
11. An assay according to claim 10 wherein said particle bound immune reactant and said unknown immune reactant are present in excess of said fluorescently labeled immune reactant, and said reacting further comprises com-petitively binding said unknown and said particle bound immune reactant with said flourescently labeled immune reactant.
12. An assay according to claim 10 wherein said fluorescently labeled immune reactant is present in excess of said unknown and said reacting further comprises first combining said fluorescently labeled immune reactant with said unknown preceding combination with particle bound immune reactant and thereafter said particle bound immune reactant is immunologically bound to the excess of said fluorescently labeled immune-reactant.
13. An assay according to claim 5 wherein the particle bound immune reactant is antigen or hapten, said fluorescently labeled immune reactant is present in excess of said particle bound immune reactant, and said reacting further comprises competitively binding said unknown and said fluorescently labeled immune reactant with said par-ticle bound immune reactant.
14. An assay according to claim 4 wherein said particle bound immune reactant is antigen or hapten, and is first reacted with said unknown preceding combination with said fluorescently labeled immune reactant.
15. An assay according to claim 5 wherein the particle bound immune reactant is antigen or hapten, is present in excess relative to said unknown and is first reacted with said unknown preceding combination with said fluorescently labeled immune reactant, and thereafter said fluorescently labeled immune reactant is immunologically bound to the excess particle bound immune reactant.
16. An assay according to claim 4 wherein said unknown is a first antibody, said fluorescently-labeled immune reactant is a second antibody immunologically homo-logous to said unknown, said particle bound immune reactant is antigen or hapten immunologically homologous to said first antibody and is first combined with said unknown and separated from said aqueous solution prior to being combined with said fluorescently labeled immune reactant whereby said unknown is immunologically bound both by said particle bound immune reactant and by said fluorescently labeled immune reactant.
17. An assay according to claim 6 wherein said unknown is a hapten or antigen which is bivalent or multi-valent, said particles have covalently bonded thereto antibody for said unknown, are present in relatively large excess to said unknown and said fluorescently labeled antibody, and said particles, said sample and said fluore-scently labeled antibody are reacted together simultaneously.
18. The assay in accordance with claim 5 wherein said fluorescently labeled immune reactant is labeled antigen or hapten and together with unknown antigen are initially concurrently present in excess of a first antibody to which they are competitively bound.
19. The assay in accordance with claim 18 wherein said antibody bonded to said particles is a second antibody for immunologically binding the combination of said com-petitively bound fluourescently labeled and unknown antigen or hapten and first antibody.
20. The assay in accordance with claim 7 wherein said fluorescently labeled immune reactant is labeled antigen or hapten and together with unknown antigen or hapthen are concurrently present in excess of said antibody bounded to said particles whereby labeled and unknown antigen or hapten are competitively immunologically bound by said particle bonded antibody.
21. The assay in accordance with claim 1 wherein said particles are formed from a member of the group of cross-linked polyacrylamide and derivatives thereof.
22. The assay in accordance with claim 1 wherein said fluorescently labeled antigen or hapten or antibody is labeled with fluorescein isothiocyanate.
23. The assay in accordance with claim 1 wherein said particles comprise a plurality of sizes with the size distribution centered around about 5 microns.
24. An immunofluorescene assay comprising:
providing a plurality of water insoluble hydrophi-lic polymeric particles of about .1-10 microns in size which form a substantially homogeneous stable aqueous suspension and having covalently bonded thereto antigen or hapten corresponding to unknown antigen or hapten to be determined immunologically, competitively binding said particles and unknown antigen-or hapten to be determined in aqueous solution with a preselected limited amount of fluorescently labeled homologous antibody to bind a portion of said labeled antibody with said particles, physically separating all of said particles from said aqueous solution thereby separating the particles from unbound labeled immune re-actant remaining in the aqueous solution, and directly mea-suring the fluorescence of a fluid suspension of said separated particles in a fluorometer, the fluorescence of labeled immune reactant bound to said particles being quantitatively related to the concentration of unknown antigen or hapten.
25. An immunofluorescence assay comprising:
providing an aqueous solution containing unknown antigen or hapten to be determined, providing fluorescently labeled corresponding antigen or hapten, competitively immunologically binding said labeled antigen or hapten and unknown antigen or hapten with a limited quantity of a homologous first antibody, adding a plurality of water insoluble hydrophilic polymeric particles of about .1-10 microns in size which form a substantially homogeneous stable aqueous suspension and having covalently bonded thereto a second antibody immunologically reactive with the reaction product of labelled antigen or hapten and unknown antigen or hapten with said first antibody for reaction therewith, physically separating all of the particles from unbound fluorescently labeled antigen or hapten remaining in the aqueous solution, and directly measuring the fluore-scence of a fluid suspension of said separated particles in a fluorometer, the fluorescence of labeled immune reactant bound to said particles being quantitatively related to the concentration of unknown antigen or hapten.
CA255,623A1975-10-091976-06-24Solid phase immunofluorescent assay methodExpiredCA1070612A (en)

Applications Claiming Priority (1)

Application NumberPriority DateFiling DateTitle
US62119775A1975-10-091975-10-09

Publications (1)

Publication NumberPublication Date
CA1070612Atrue CA1070612A (en)1980-01-29

Family

ID=24489155

Family Applications (1)

Application NumberTitlePriority DateFiling Date
CA255,623AExpiredCA1070612A (en)1975-10-091976-06-24Solid phase immunofluorescent assay method

Country Status (7)

CountryLink
JP (1)JPS6010578B2 (en)
BR (1)BR7605664A (en)
CA (1)CA1070612A (en)
DE (1)DE2641713A1 (en)
FR (1)FR2327546A1 (en)
GB (1)GB1552374A (en)
IT (1)IT1066186B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
CA1111762A (en)*1977-12-281981-11-03David S. FrankFluorescent rare earth chelate in polymeric latex particles
US4171311A (en)*1978-01-161979-10-16International Diagnostics Tech. Inc.Imides of thyroxin and triiodothyronine
EP0030087A1 (en)*1979-11-131981-06-10Technicon Instruments Company LimitedImmunoassay method and apparatus and kit for carrying out the method
EP0046563B1 (en)*1980-08-221985-04-10Laboratorium Prof. Dr. Rudolf BertholdProcess for performing analytical determinations by means of the chemiluminescent method, and application of this process to immuno assays
IT1140209B (en)*1981-09-251986-09-24Anic Spa IMMUNOLUORESCENCE REAGENTS AND METHOD FOR THEIR PREPARATION
JPS59108111U (en)*1983-01-101984-07-20ダイキン工業株式会社 Hot water storage type water heater
JPS59220271A (en)*1983-05-271984-12-11Kawasaki Heavy Ind Ltd Composite casting method
GB8401368D0 (en)*1984-01-191984-02-22Amersham Int PlcAssay method
CN111007241A (en)*2019-12-202020-04-14苏州和迈精密仪器有限公司 Fluorescence competitive immunoassay method, device and application based on double-layer porous membrane

Also Published As

Publication numberPublication date
GB1552374A (en)1979-09-12
DE2641713A1 (en)1977-04-21
BR7605664A (en)1977-08-23
JPS5246884A (en)1977-04-14
JPS6010578B2 (en)1985-03-18
IT1066186B (en)1985-03-04
FR2327546A1 (en)1977-05-06
FR2327546B3 (en)1979-04-13

Similar Documents

PublicationPublication DateTitle
US4254096A (en)Reagent combination for solid phase immunofluorescent assay
US4201763A (en)Solid phase immunofluorescent assay method
EP0201079B1 (en)Delayed solid phase immunologic assay
US4506009A (en)Heterogeneous immunoassay method
US4289747A (en)Immunological determination using lectin
US4925788A (en)Immunoassay system and procedure based on precipitin-like interaction between immune complex and Clq or other non-immunospecific factor
US4185084A (en)Immunochemical measuring method using second antigenic substance
CA1200482A (en)Double antibody conjugate
US6303325B1 (en)Method for detecting analytes
JPH0340341B2 (en)
JP2636331B2 (en) One-step assay for antigen-specific antibodies and suitable reagents
US5650333A (en)Immunoassay method and kit using superaggregated complex
US5362655A (en)Process for the determination of a specifically bindable substance
US4088746A (en)Radioimmunoassay for thyroid-stimulating hormone (TSH)
CA1070612A (en)Solid phase immunofluorescent assay method
CA1146853A (en)Method of passively adsorbing immuno-reactive haptens to solid phases
JPH1078435A (en)Rise of sensitivity in immunochemical measurement for material to be inspected
JP2736058B2 (en) Manufacturing method of immunoassay device
CA2002470A1 (en)Method of assay for antigen
EP0308235B1 (en)Attachment of compounds to polymeric particles using carbamoylonium compounds
EP0389301A2 (en)Reagent complex for immunoassay
WO1984003358A1 (en)Insoluble surfaces treated to inhibit non-specific protein binding
JPH04203968A (en)Method for measuring chemical emission immunity
US5989922A (en)Method for determining rheumatoid factors and agents for carrying out the method
JPH0688822A (en)Method for measuring material to be analyzed in aqueous sample, measuring reagent and measuring reagent kit

Legal Events

DateCodeTitleDescription
MKEXExpiry

[8]ページ先頭

©2009-2025 Movatter.jp